Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Multiple Myeloma 22 Recurrence 4 Neoplasms 3 Plasmablastic Lymphoma 2 Leukemia, Myeloid, Acute 2 Smoldering Multiple Myeloma 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Plasmacytoma 1 Myelodysplastic Syndromes 1 Lymphoma, Large B-Cell, Diffuse 1 Lymphoma 1 Leukemia, Plasma Cell 1 Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 59 Carboplatin 56 Pemetrexed 47 Cisplatin 39 Paclitaxel 24 Nivolumab 23 Docetaxel 21 durvalumab 20 Gemcitabine 15 130-nm albumin-bound paclitaxel 14 osimertinib 13 Cetuximab 12 Specimen Handling 11 Magnetic Resonance Spectroscopy 11 atezolizumab 10 amivantamab 8 Taxes 8 Radiotherapy 8 Radiosurgery 7 Ipilimumab 7 lazertinib 6 alectinib 6 Ramucirumab 6 Observation 6 Bevacizumab 6 cemiplimab 5 Leucovorin 5 Fluorouracil 5 Etoposide 5 Erlotinib Hydrochloride 5

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Carcinoma, Non-Small-Cell Lung × daratumumab × 30 days × Clear all

NCT06015724 2026-05-15

DARANIVOVAX

Georgetown University

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon ⚡